In the previous post, GLP-1 agonists’ analysis revealed an extraordinary increase of 327% in spending over the years. This enormous increase makes us wonder about the trends of other anti-diabetics. In this post, we will explore the contribution of another drug class named SGLT2 Inhibitors towards Medicare Part D spending.